Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

BACKGROUND: Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC. MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Knödler, Maren, Körfer, Justus, Kunzmann, Volker, Trojan, Jörg, Daum, Severin, Schenk, Michael, Kullmann, Frank, Schroll, Sebastian, Behringer, Dirk, Stahl, Michael, Al-Batran, Salah-Eddin, Hacker, Ulrich, Ibach, Stefan, Lindhofer, Horst, Lordick, Florian
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6070920/
https://ncbi.nlm.nih.gov/pubmed/29988111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0150-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados